Clinical Trial Update: Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD [Phase 3]

View source ↗

Summary

Phase 3 trial update for brolucizumab 6 mg in neovascular age-related macular degeneration has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• brolucizumab 6 mg (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2020-04-30